GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Short Percentage of Float

Gensight Biologics (XPAR:SIGHT) Short Percentage of Float


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Gensight Biologics's Short Percentage of Float

For the Biotechnology subindustry, Gensight Biologics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's Short Percentage of Float falls into.


;
;

Gensight Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:POXEL XPAR:ALDVI XPAR:ALGEN XPAR:ALVAL XPAR:AELIS XPAR:ALCOX XPAR:ALNFL XPAR:ALPAT XPAR:ALVIO XPAR:ALTHX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0RIM:UK
Address
74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Website
https://www.gensight-biologics.com
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology, where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics Headlines

No Headlines